Trial Information
A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes
Inclusion Criteria:
- MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long
as their IPSS score ≤ 1.5.
Exclusion Criteria:
- Pregnant women and nursing women will be excluded.
- History of clinically significant liver or kidney disease.
- ECOG>2
- IPSS score >1.5
- Poorly controlled diabetes mellitus, hypertension, or other serious medical or
psychiatric illness that could potentially interfere with the completion of treatment
according to the protocol.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
major hematologic improvement in any lineage
Principal Investigator
moshe e gatt, dr
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hadassah Medical Organization
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
385-mds 1-HMO-CTIL
NCT ID:
NCT00247026
Start Date:
April 2007
Completion Date:
Related Keywords:
- Myelodysplastic Syndrome
- myelodysplasia
- curcumin
- coenzyme Q10
- cytopenia
- Myelodysplastic Syndromes
- Preleukemia